METHOD FOR ASSESSING THE RISK OF STRUCTURAL AND METABOLIC BONE DISORDERS IN WOMEN SUFFERING TYPE 2 DIABETES MELLITUS Russian patent published in 2019 - IPC A61B5/107 A61B6/00 G01N33/50 

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to endocrinology, and can be used to assess the risk of structural and metabolic bone disorders in women suffering type 2 diabetes mellitus. Clinical examination, osteodensitometry and trabecular bone index (TBS) are stated. An age, a body mass index (BMI) and content of bone remodeling markers: osteocalcin, N-terminal propeptide procollagen type 1 (P1NP), C-terminal telopeptides of collagen type I (beta-Cross Laps) are determined. After that coefficients F1, F2, F3 and F4 are determined by formulas: F1=-203.307+3.384⋅X1+0.664⋅X2+0.050⋅X3+163.659⋅X4+0.469⋅X5-23.776⋅X6; F2=-183.324+3.298⋅X1+0.537⋅X2+0.687⋅X3+141.658⋅X4+0.290⋅X5-14.458⋅X6; F3=-247.826+4.174⋅X1+0.872⋅X2+0.258⋅X3+159.068⋅X4+0.447⋅X5-19.092⋅X6; F4=-233.298+4.233⋅X1+0.568⋅X2+0.548⋅X3+144.849⋅X4+0.334⋅X5-11.456⋅X6, where X1 is age, years; X2 is the level of osteocalcin, ng/ml; X3 - BMI, kg/m²; X4 is the TBS index; X5 – level P1NP, ng/ml; X6 is the level of beta-Cross Laps, ng/ml. If F1 is more than F2, F3, F4 is considered to be a low risk. If F2 is more than F1, F3, F4, as well as F3 is more than F1, F2, F4 is intermediate risk. If F4 is more than F1, F2 and F3 – high risk of developing structural and metabolic bone disorders.

EFFECT: method provides the accurate assessment of the risk of developing early structural metabolic bone disorders in the patients with type 2 diabetes mellitus, irrespective of age (reproductive and postmenopausal period) due to clinical examination of patient, osteodensitometry with determination of TBS value – indirect index of trabecular microarchitectonics and determination of content of bone remodeling markers.

1 cl, 4 ex